Ilyang Pharmaceuticals Tuesday released its phase 3 clinical trial result of Supect (Ingredient: Radotinib), an anti-chronic myelogenous leukemia treatment. The research examined 241 patients diagnosed with chronic myelogenous leukemia for the first time at 24 university hospitals in five Asian countries.
“After treating patients with Supect for a year, the major gene-reaction was twice as more than those treated with Glivec (Ingredient: Imatinib), said Professors Kwak Jae-yong 곽재용 of Chonbuk National University Hospital 전북대병원, and Kim Dong-wook 김동욱 of Seoul St. Mary’s Hospital 서울성모병원.
The drug’s long-term response rate and early molecular response, which outlines the three-month initial evaluation of prolonged response rates or survival rates, was higher than Glivec, they said.
Due to the medicine’s full gene response rate, the percentage of patients who can afford to stop taking the drug eventually will increase even more when the treatment is used for patients diagnosed with chronic myelogenous leukemia for the first time, they added.
“The company expects patients in the whole world will welcome Supect as the most economical drug among the next-generation, targeted cancer treatments,” a company 일양제약 official said.
The results of the study were published in a recent edition of “Clinical Cancer Research,” one of the most influential cancer-related journals.
<© Korea Biomedical Review, All rights reserved.>